Migraine Drugs Market By Treatment, Therapeutic Class and Route of Administration - Global Industry Analysis And Forecast To 2027
Published On : October 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC101448
Migraine Drugs Market By Treatment (Preventive Treatment and Acute Treatment), Therapeutic Class (CGRP Monoclonal Antibodies, Triptans, CGRP Small Molecule Antagonists, Acetylcholine Inhibitors/ Neurotoxins, Ditans, Ergot Alkaloids, Nsaids and Other Therapeutic Class) and Route of Administration (Injectables, Oral and Other Route of Administration) - Global Industry Analysis And Forecast To 2027
Industry Outlook
The migraine is a major issue related to headache described by intermittent headaches which are moderate to severe. Basically, the headaches influence one portion of the head, are throbbing in nature, and may last in between two to 72 hours. The related indications may incorporate vomiting, sensitivity, and nausea to smell, light, or sound. The torment is for the most part exacerbated by physical activity. Up to 33% of individuals have an atmosphere: basically a brief time of the visual aggravation that flags that the migraine will soon happen. Occasionally, the aura may happen with practically no headache succeeding it. The frequency of migraine can be reduced by; reducing stress, drinking enough water, stop eating some foods, physical exercise regularly, etc. Therefore, the Migraine Drugs Market is anticipated to expand and has tremendous scope during the forecast period. The global Migraine Drugs Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Drivers & Restrains
The drivers of this market are; the rise in the activities of research and development for more efficient for the treatment of this disorder, increase in the number of population suffering from this disorder, improvement in the healthcare sector across the globe, more novel drugs been developed for the treatment of the disorder, and various other factors. The restraining factor of the market can be the cost of the drugs that are been developed recently.
Regional Insights
The North American region is leading the global Migraine Drugs Market owing rise in the number of cases, rising utilization of the innovative therapeutics, most of the target population comes from this region, etc.
Migraine Drugs Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Pfizer
- Allergan
- Eli Lilly
- Amgen
- GlaxoSmithKline
- Teva Pharma
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Migraine Drugs Market, By Treatment, Estimates and Forecast, 2017-2027 ($Million)
o Preventive Treatment
o Acute Treatment
o Migraine Drugs Market, By Therapeutic Class, Estimates and Forecast, 2017-2027 ($Million)
o CGRP Monoclonal Antibodies
o Triptans
o CGRP Small Molecule Antagonists
o Acetylcholine Inhibitors/ Neurotoxins
o Ditans
o Ergot Alkaloids
o Nsaids
o Other Therapeutic Class
o Migraine Drugs Market, By Route of Administration, Estimates and Forecast, 2017-2027 ($Million)
o Injectables
o Oral
o Other Route of Administration
o Migraine Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Migraine Drugs Market, By Country
o U.S. Migraine Drugs Market
o Canada Migraine Drugs Market
o Mexico Migraine Drugs Market
o Europe
§ Europe Migraine Drugs Market, By Country
o Germany Migraine Drugs Market
o UK Migraine Drugs Market
o France Migraine Drugs Market
o Russia Migraine Drugs Market
o Italy Migraine Drugs Market
o Rest of Europe Migraine Drugs Market
o Asia-Pacific
§ Asia-Pacific Migraine Drugs Market, By Country
o China Migraine Drugs Market
o Japan Migraine Drugs Market
o South Korea Migraine Drugs Market
o India Migraine Drugs Market
o Southeast Asia Migraine Drugs Market
o Rest of Asia-Pacific Migraine Drugs Market
o South America
§ South America Migraine Drugs Market, By Country
o Brazil Migraine Drugs Market
o Argentina Migraine Drugs Market
o Columbia Migraine Drugs Market
o Rest of South America Migraine Drugs Market
o Middle East and Africa
§ Middle East and Africa Migraine Drugs Market, By Country
o Saudi Arabia Migraine Drugs Market
o UAE Migraine Drugs Market
o Egypt Migraine Drugs Market
o Nigeria Migraine Drugs Market
o South Africa Migraine Drugs Market
o Rest of MEA Migraine Drugs Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Migraine Drugs Market, By Treatment
5.1. Introduction
5.2. Global Migraine Drugs Revenue and Market Share by Treatment (2017-2027)
5.2.1. Global Migraine Drugs Revenue and Revenue Share by Treatment (2017-2027)
5.3. Preventive Treatment
5.3.1. Global Preventive Treatment Revenue and Growth Rate (2017-2027)
5.4. Acute Treatment
5.4.1. Global Acute Treatment Revenue and Growth Rate (2017-2027)
6. Migraine Drugs Market, By Therapeutic Class
6.1. Introduction
6.2. Global Migraine Drugs Revenue and Market Share by Therapeutic Class (2017-2027)
6.2.1. Global Migraine Drugs Revenue and Revenue Share by Therapeutic Class (2017-2027)
6.3. CGRP Monoclonal Antibodies
6.3.1. Global CGRP Monoclonal Antibodies Revenue and Growth Rate (2017-2027)
6.4. Triptans
6.4.1. Global Triptans Revenue and Growth Rate (2017-2027)
6.5. CGRP Small Molecule Antagonists
6.5.1. Global CGRP Small Molecule Antagonists Revenue and Growth Rate (2017-2027)
6.6. Acetylcholine Inhibitors/ Neurotoxins
6.6.1. Global Acetylcholine Inhibitors/ Neurotoxins Revenue and Growth Rate (2017-2027)
6.7. Ditans
6.7.1. Global Ditans Revenue and Growth Rate (2017-2027)
6.8. Ergot Alkaloids
6.8.1. Global Ergot Alkaloids Revenue and Growth Rate (2017-2027)
6.9. Nsaids
6.9.1. Global Nsaids Revenue and Growth Rate (2017-2027)
6.10. Other Therapeutic Class
6.10.1. Global Other Therapeutic Class Revenue and Growth Rate (2017-2027)
7. Migraine Drugs Market, By Route Of Administration
7.1. Introduction
7.2. Global Migraine Drugs Revenue and Market Share by Route Of Administration (2017-2027)
7.2.1. Global Migraine Drugs Revenue and Revenue Share by Route Of Administration (2017-2027)
7.3. Injectables
7.3.1. Global Injectables Revenue and Growth Rate (2017-2027)
7.4. Oral
7.4.1. Global Oral Revenue and Growth Rate (2017-2027)
7.5. Other Route of Administration
7.5.1. Global Other Route of Administration Revenue and Growth Rate (2017-2027)
8. Migraine Drugs Market, By Region
8.1. Introduction
8.2. Global Migraine Drugs Revenue and Market Share by Regions
8.2.1. Global Migraine Drugs Revenue by Regions (2017-2027)
8.3. North America Migraine Drugs by Countries
8.3.1. North America Migraine Drugs Revenue and Growth Rate (2017-2027)
8.3.2. North America Migraine Drugs Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Migraine Drugs by Countries
8.4.1. Europe Migraine Drugs Revenue and Growth Rate (2017-2027)
8.4.2. Europe Migraine Drugs Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Migraine Drugs by Countries
8.5.1. Asia-Pacific Migraine Drugs Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Migraine Drugs Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Migraine Drugs by Countries
8.6.1. South America Migraine Drugs Revenue and Growth Rate (2017-2027)
8.6.2. South America Migraine Drugs Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Migraine Drugs by Countries
8.7.1. Middle East and Africa Migraine Drugs Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Migraine Drugs Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Pfizer
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Revenue and Market Share
9.2. Allergan
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Revenue and Market Share
9.3. Eli Lilly
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Revenue and Market Share
9.4. Amgen
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Revenue and Market Share
9.5. GlaxoSmithKline
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Revenue and Market Share
9.6. Teva Pharma
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Revenue and Market Share
10. Global Migraine Drugs Market Competition, by Manufacturer
10.1. Global Migraine Drugs Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Migraine Drugs Price By Region (2017-2017)
10.3. Top 5 Migraine Drugs Manufacturer Market Share
10.4. Market Competition Trend
11. Migraine Drugs Market Forecast (2017-2027)
11.1. Global Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Migraine Drugs Market Forecast by Regions (2017-2027)
11.2.1. North America Migraine Drugs Market Forecast (2017-2027)
11.2.1.1. United States Migraine Drugs Market Forecast (2017-2027)
11.2.1.2. Canada Migraine Drugs Market Forecast (2017-2027)
11.2.1.3. Mexico Migraine Drugs Market Forecast (2017-2027)
11.2.2. Europe Migraine Drugs Market Forecast (2017-2027)
11.2.2.1. Germany Migraine Drugs Market Forecast (2017-2027)
11.2.2.2. France Migraine Drugs Market Forecast (2017-2027)
11.2.2.3. UK Migraine Drugs Market Forecast (2017-2027)
11.2.2.4. Russia Migraine Drugs Market Forecast (2017-2027)
11.2.2.5. Italy Migraine Drugs Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Migraine Drugs Market Forecast (2017-2027)
11.2.3. Asia-Pacific Migraine Drugs Market Forecast (2017-2027)
11.2.3.1. China Migraine Drugs Market Forecast (2017-2027)
11.2.3.2. Japan Migraine Drugs Market Forecast (2017-2027)
11.2.3.3. Korea Migraine Drugs Market Forecast (2017-2027)
11.2.3.4. India Migraine Drugs Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Migraine Drugs Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Migraine Drugs Market Forecast (2017-2027)
11.2.4. South America Migraine Drugs Market Forecast (2017-2027)
11.2.4.1. Brazil Migraine Drugs Market Forecast (2017-2027)
11.2.4.2. Argentina Migraine Drugs Market Forecast (2017-2027)
11.2.4.3. Columbia Migraine Drugs Market Forecast (2017-2027)
11.2.4.4. Rest of South America Migraine Drugs Market Forecast (2017-2027)
11.2.5. Middle East and Africa Migraine Drugs Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Migraine Drugs Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Migraine Drugs Market Forecast (2017-2027)
11.2.5.3. Egypt Migraine Drugs Market Forecast (2017-2027)
11.2.5.4. Nigeria Migraine Drugs Market Forecast (2017-2027)
11.2.5.5. South Africa Migraine Drugs Market Forecast (2017-2027)
11.2.5.6. Turkey Migraine Drugs Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Migraine Drugs Market Forecast (2017-2027)
11.3. Migraine Drugs Market Forecast by Treatment (2017-2027)
11.3.1. Migraine Drugs Forecast by Treatment (2017-2027)
11.3.2. Migraine Drugs Market Share Forecast by Treatment (2017-2027)
11.4. Migraine Drugs Market Forecast by Therapeutic Class (2017-2027)
11.4.1. Migraine Drugs Forecast by Therapeutic Class (2017-2027)
11.4.2. Migraine Drugs Market Share Forecast by Therapeutic Class (2017-2027)
11.5. Migraine Drugs Market Forecast by Route Of Administration (2017-2027)
11.5.1. Migraine Drugs Forecast by Route Of Administration (2017-2027)
11.5.2. Migraine Drugs Market Share Forecast by Route Of Administration (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Migraine Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Migraine Drugs Revenue and Revenue Share by Treatment (2017-2018)
Figure Global Preventive Treatment Revenue and Growth Rate (2017-2018)
Figure Global Acute Treatment Revenue and Growth Rate (2017-2018)
Table Global Migraine Drugs Revenue and Revenue Share by Therapeutic Class (2017-2018)
Figure Global CGRP Monoclonal Antibodies Revenue and Growth Rate (2017-2018)
Figure Global Triptans Revenue and Growth Rate (2017-2018)
Figure Global CGRP Small Molecule Antagonists Revenue and Growth Rate (2017-2018)
Figure Global Acetylcholine Inhibitors/ Neurotoxins Revenue and Growth Rate (2017-2018)
Figure Global Ditans Revenue and Growth Rate (2017-2018)
Figure Global Ergot Alkaloids Revenue and Growth Rate (2017-2018)
Figure Global Nsaids Revenue and Growth Rate (2017-2018)
Figure Global Other Therapeutic Class Revenue and Growth Rate (2017-2018)
Table Global Migraine Drugs Revenue and Revenue Share by Route Of Administration (2017-2018)
Figure Global Injectables Revenue and Growth Rate (2017-2018)
Figure Global Oral Revenue and Growth Rate (2017-2018)
Figure Global Other Route of Administration Revenue and Growth Rate (2017-2018)
Table Global Migraine Drugs Revenue by Regions (2017-2018)
Figure North America Migraine Drugs Growth Rate (2017-2018)
Figure North America Migraine Drugs Revenue and Growth Rate (2017-2018)
Figure North America Migraine Drugs by Countries (2017-2018)
Figure North America Migraine Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Migraine Drugs Growth Rate (2017-2018)
Figure United States Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Migraine Drugs Growth Rate (2017-2018)
Figure Canada Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Migraine Drugs Growth Rate (2017-2018)
Figure Mexico Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Migraine Drugs Growth Rate (2017-2018)
Figure Europe Migraine Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Migraine Drugs by Countries (2017-2018)
Figure Europe Migraine Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Migraine Drugs Growth Rate (2017-2018)
Figure Germany Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Migraine Drugs Growth Rate (2017-2018)
Figure France Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Migraine Drugs Growth Rate (2017-2018)
Figure UK Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Migraine Drugs Growth Rate (2017-2018)
Figure Russia Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Migraine Drugs Growth Rate (2017-2018)
Figure Italy Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Migraine Drugs Growth Rate (2017-2018)
Figure Rest of Europe Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Migraine Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Migraine Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Migraine Drugs by Countries (2017-2018)
Figure Asia-Pacific Migraine Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Migraine Drugs Growth Rate (2017-2018)
Figure China Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Migraine Drugs Growth Rate (2017-2018)
Figure Japan Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Migraine Drugs Growth Rate (2017-2018)
Figure Korea Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Migraine Drugs Growth Rate (2017-2018)
Figure India Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Migraine Drugs Growth Rate (2017-2018)
Figure Southeast Asia Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Migraine Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Migraine Drugs Growth Rate (2017-2018)
Figure South America Migraine Drugs Revenue and Growth Rate (2017-2018)
Figure South America Migraine Drugs by Countries (2017-2018)
Figure South America Migraine Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Migraine Drugs Growth Rate (2017-2018)
Figure Brazil Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Migraine Drugs Growth Rate (2017-2018)
Figure Argentina Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Migraine Drugs Growth Rate (2017-2018)
Figure Columbia Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Migraine Drugs Growth Rate (2017-2018)
Figure Rest of South America Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Migraine Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Migraine Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Migraine Drugs by Countries (2017-2018)
Figure Middle East and Africa Migraine Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Migraine Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Migraine Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Migraine Drugs Growth Rate (2017-2018)
Figure Egypt Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Migraine Drugs Growth Rate (2017-2018)
Figure Nigeria Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Migraine Drugs Growth Rate (2017-2018)
Figure South Africa Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Migraine Drugs Growth Rate (2017-2018)
Figure Turkey Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Migraine Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Migraine Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Pfizer Migraine Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Allergan Migraine Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Eli Lilly Migraine Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Amgen Migraine Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GlaxoSmithKline Migraine Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Teva Pharma Migraine Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Migraine Drugs Market Share by Manufacturer
Figure Global Migraine Drugs Revenue and Market Share by Manufacturer
Table Global Migraine Drugs Price by Region (2017-2017)
Figure Top 5 Migraine Drugs Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Migraine Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Migraine Drugs Market Forecast by Regions (2018-2025)
Figure North America Migraine Drugs Market Forecast (2018-2025)
Figure United States Migraine Drugs Market Forecast (2018-2025)
Figure Canada Migraine Drugs Market Forecast (2018-2025)
Figure Mexico Migraine Drugs Market Forecast (2018-2025)
Figure Europe Migraine Drugs Market Forecast (2018-2025)
Figure Germany Migraine Drugs Market Forecast (2018-2025)
Figure France Migraine Drugs Market Forecast (2018-2025)
Figure UK Migraine Drugs Market Forecast (2018-2025)
Figure Russia Migraine Drugs Market Forecast (2018-2025)
Figure Italy Migraine Drugs Market Forecast (2018-2025)
Figure Rest of Europe Migraine Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Migraine Drugs Market Forecast (2018-2025)
Figure China Migraine Drugs Market Forecast (2018-2025)
Figure Japan Migraine Drugs Market Forecast (2018-2025)
Figure Korea Migraine Drugs Market Forecast (2018-2025)
Figure India Migraine Drugs Market Forecast (2018-2025)
Figure Southeast Asia Migraine Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Migraine Drugs Market Forecast (2018-2025)
Figure South America Migraine Drugs Market Forecast (2018-2025)
Figure Brazil Migraine Drugs Market Forecast (2018-2025)
Figure Argentina Migraine Drugs Market Forecast (2018-2025)
Figure Columbia Migraine Drugs Market Forecast (2018-2025)
Figure Rest of South America Migraine Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Migraine Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Migraine Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Migraine Drugs Market Forecast (2018-2025)
Figure Egypt Migraine Drugs Market Forecast (2018-2025)
Figure Nigeria Migraine Drugs Market Forecast (2018-2025)
Figure South Africa Migraine Drugs Market Forecast (2018-2025)
Figure Turkey Migraine Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Migraine Drugs Market Forecast (2018-2025)
Figure Global Migraine Drugs Forecast by Treatment (2018-2025)
Figure Global Migraine Drugs Market Share Forecast by Treatment (2018-2025)
Figure Global Migraine Drugs Forecast by Treatment (2018-2025)
Figure Global Migraine Drugs Forecast by Therapeutic Class (2018-2025)
Figure Global Migraine Drugs Market Share Forecast by Therapeutic Class (2018-2025)
Figure Global Migraine Drugs Forecast by Therapeutic Class (2018-2025)
Figure Global Migraine Drugs Forecast by Route Of Administration (2018-2025)
Figure Global Migraine Drugs Market Share Forecast by Route Of Administration (2018-2025)
Figure Global Migraine Drugs Forecast by Route Of Administration (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|